Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NOW stock price vs ELV: inconclusive — current versus $28.17 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ELV's multiple
Implied fair value · at NOW's multiple
Needs NOW P/E.
Snapshot Sep 11, 2026, 10:00 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 74% equity / 26% debt · EV / Revenue 0.58x · EV proxy / EBITDA proxy 14.49x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ServiceNow, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ELEVANCE HEALTH, INC. · implied price per share
Bear
$190.58
Base
$247.47
Bull
$324.22
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
MICROSOFT CORP
NOW vs MSFT
ADOBE INC.
NOW vs ADBE
ORACLE CORP
NOW vs ORCL
Salesforce, Inc.
NOW vs CRM
INTERNATIONAL BUSINESS MACHINES CORP
NOW vs IBM
Paycom Software, Inc.
NOW vs PAYC
UnitedHealth Group Incorporated
NOW vs UNH
CVS Health Corporation
NOW vs CVS
HUMANA INC
NOW vs HUM
CENTENE CORP
NOW vs CNC
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe NOW can sustain 20%+ revenue growth and maintain high-teens to low-20s profitability, then hold only if you are comfortable paying a large premium; otherwise, reduce exposure because the current price is far above both ELV-implied and DCF valuation ranges.
NOW trades at a steep premium to ELV across earnings, sales, and cash-flow proxies, but the implied P/E-based price of $24.90 is far below the current price of $111.23. The valuation gap is driven by NOW’s much richer growth profile and higher margins, yet the market is still paying 66.6x earnings versus 14.9x for ELV.
Supporting Metrics
